BR0306701A - Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal - Google Patents
Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um salInfo
- Publication number
- BR0306701A BR0306701A BR0306701-7A BR0306701A BR0306701A BR 0306701 A BR0306701 A BR 0306701A BR 0306701 A BR0306701 A BR 0306701A BR 0306701 A BR0306701 A BR 0306701A
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- salts
- compound
- alkyl
- preparing
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 11
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 Compound Salt Chemical class 0.000 title abstract 2
- 159000000007 calcium salts Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910003002 lithium salt Inorganic materials 0.000 abstract 1
- 159000000002 lithium salts Chemical class 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003751 zinc Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075621 | 2002-01-16 | ||
| NL1019762 | 2002-01-17 | ||
| PCT/EP2003/000515 WO2003059939A1 (en) | 2002-01-16 | 2003-01-15 | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306701A true BR0306701A (pt) | 2004-12-28 |
Family
ID=26077601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306701-7A BR0306701A (pt) | 2002-01-16 | 2003-01-15 | Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6998398B2 (enExample) |
| EP (1) | EP1468010A1 (enExample) |
| JP (1) | JP4384495B2 (enExample) |
| KR (1) | KR100979077B1 (enExample) |
| CN (1) | CN100591689C (enExample) |
| AU (1) | AU2003206755B2 (enExample) |
| BR (1) | BR0306701A (enExample) |
| CA (1) | CA2473447A1 (enExample) |
| HR (1) | HRP20040560A2 (enExample) |
| IL (1) | IL162645A0 (enExample) |
| MX (1) | MXPA04006887A (enExample) |
| NO (1) | NO330528B1 (enExample) |
| PL (1) | PL371511A1 (enExample) |
| RU (1) | RU2303041C2 (enExample) |
| WO (1) | WO2003059939A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050009031A (ko) * | 2003-07-15 | 2005-01-24 | 엘지전자 주식회사 | 1회 기록 가능한 광디스크 및 광디스크의 관리정보 기록방법 |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| AR046454A1 (es) * | 2003-11-18 | 2005-12-07 | Solvay Pharm Gmbh | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| MX2007006279A (es) | 2004-12-15 | 2007-06-14 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa. |
| US20060159748A1 (en) * | 2004-12-23 | 2006-07-20 | Rajesh Jain | Oral immediate release formulation of a poorly water-soluble active substance |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| WO2007054975A1 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| PL424453A1 (pl) | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
-
2003
- 2003-01-15 PL PL03371511A patent/PL371511A1/xx not_active Application Discontinuation
- 2003-01-15 AU AU2003206755A patent/AU2003206755B2/en not_active Ceased
- 2003-01-15 RU RU2004124840/04A patent/RU2303041C2/ru not_active IP Right Cessation
- 2003-01-15 WO PCT/EP2003/000515 patent/WO2003059939A1/en not_active Ceased
- 2003-01-15 EP EP03704436A patent/EP1468010A1/en not_active Withdrawn
- 2003-01-15 MX MXPA04006887A patent/MXPA04006887A/es active IP Right Grant
- 2003-01-15 IL IL16264503A patent/IL162645A0/xx not_active IP Right Cessation
- 2003-01-15 CN CN03802391A patent/CN100591689C/zh not_active Expired - Fee Related
- 2003-01-15 KR KR1020047010938A patent/KR100979077B1/ko not_active Expired - Fee Related
- 2003-01-15 BR BR0306701-7A patent/BR0306701A/pt not_active Application Discontinuation
- 2003-01-15 HR HR20040560A patent/HRP20040560A2/hr not_active Application Discontinuation
- 2003-01-15 CA CA002473447A patent/CA2473447A1/en not_active Abandoned
- 2003-01-15 JP JP2003560041A patent/JP4384495B2/ja not_active Expired - Lifetime
-
2004
- 2004-07-14 US US10/890,392 patent/US6998398B2/en not_active Expired - Fee Related
- 2004-08-06 NO NO20043295A patent/NO330528B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100979077B1 (ko) | 2010-08-31 |
| EP1468010A1 (en) | 2004-10-20 |
| US20050038012A1 (en) | 2005-02-17 |
| KR20040089106A (ko) | 2004-10-20 |
| CN1617883A (zh) | 2005-05-18 |
| AU2003206755B2 (en) | 2008-07-17 |
| NO330528B1 (no) | 2011-05-09 |
| JP4384495B2 (ja) | 2009-12-16 |
| IL162645A0 (en) | 2005-11-20 |
| RU2303041C2 (ru) | 2007-07-20 |
| US6998398B2 (en) | 2006-02-14 |
| CN100591689C (zh) | 2010-02-24 |
| HRP20040560A2 (en) | 2004-10-31 |
| JP2005520809A (ja) | 2005-07-14 |
| RU2004124840A (ru) | 2006-01-20 |
| CA2473447A1 (en) | 2003-07-24 |
| MXPA04006887A (es) | 2004-12-06 |
| PL371511A1 (en) | 2005-06-27 |
| NO20043295L (no) | 2004-08-06 |
| WO2003059939A1 (en) | 2003-07-24 |
| HK1072946A1 (zh) | 2005-09-16 |
| AU2003206755A1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| DE60315674D1 (de) | Neue imidazopyridine und ihre verwendung | |
| WO2008019967A3 (en) | Phenyl, pyridine and quinoline derivatives | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| ATE517882T1 (de) | Chinolinderivate | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| BG108650A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| UA89123C2 (ru) | Производные пиримидина для лечения абнормального роста клеток | |
| NO20050134L (no) | Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse | |
| EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| BR0306701A (pt) | Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2007125398A3 (en) | : sulfonamide compounds as antagonists of the n-type calcium channel | |
| MX2010003983A (es) | 5,6-diarilpiridinas sustituidas en la posicion 2 y 3, su preparacion y su uso terapeutico. | |
| BR0308419A (pt) | Derivados de azetidina como antagonistas do receptor ccr-3 | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| ATE273277T1 (de) | Piperidinyl- und n-amidinopiperidinyl-derivate | |
| BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda | |
| JP2012504584A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |